nodes	percent_of_prediction	percent_of_DWPC	metapath
Tripelennamine—CYP2D6—Parkinson's disease	0.984	1	CbGaD
Tripelennamine—Pargyline—MAOB—Parkinson's disease	0.00137	0.102	CrCbGaD
Tripelennamine—Pargyline—MAOA—Parkinson's disease	0.000958	0.0713	CrCbGaD
Tripelennamine—Alverine—HTR1A—Parkinson's disease	0.000916	0.0681	CrCbGaD
Tripelennamine—Captodiame—DRD3—Parkinson's disease	0.000888	0.0661	CrCbGaD
Tripelennamine—Benzphetamine—SLC18A2—Parkinson's disease	0.00076	0.0566	CrCbGaD
Tripelennamine—Chlorphenamine—SLC6A3—Parkinson's disease	0.000372	0.0277	CrCbGaD
Tripelennamine—Rosiglitazone—CYP2D6—Parkinson's disease	0.000366	0.0273	CrCbGaD
Tripelennamine—Mepyramine—CYP2D6—Parkinson's disease	0.000364	0.0271	CrCbGaD
Tripelennamine—Aprindine—CYP2D6—Parkinson's disease	0.000329	0.0245	CrCbGaD
Tripelennamine—Benzphetamine—SLC6A3—Parkinson's disease	0.000315	0.0235	CrCbGaD
Tripelennamine—Carbinoxamine—CYP2E1—Parkinson's disease	0.000313	0.0233	CrCbGaD
Tripelennamine—Cyclobenzaprine—HTR2A—Parkinson's disease	0.000306	0.0228	CrCbGaD
Tripelennamine—Cyclobenzaprine—CYP2D6—Parkinson's disease	0.00028	0.0208	CrCbGaD
Tripelennamine—Brompheniramine—CYP2E1—Parkinson's disease	0.000272	0.0202	CrCbGaD
Tripelennamine—Carbinoxamine—CYP2D6—Parkinson's disease	0.00023	0.0171	CrCbGaD
Tripelennamine—Promazine—DRD1—Parkinson's disease	0.00023	0.0171	CrCbGaD
Tripelennamine—Imipramine—HTR7—Parkinson's disease	0.000218	0.0162	CrCbGaD
Tripelennamine—Amitriptyline—HTR7—Parkinson's disease	0.000217	0.0161	CrCbGaD
Tripelennamine—Doxepin—HTR1A—Parkinson's disease	0.000215	0.016	CrCbGaD
Tripelennamine—Amitriptyline—DRD3—Parkinson's disease	0.000204	0.0152	CrCbGaD
Tripelennamine—Bepridil—CYP2D6—Parkinson's disease	0.000203	0.0151	CrCbGaD
Tripelennamine—Brompheniramine—CYP2D6—Parkinson's disease	0.000199	0.0148	CrCbGaD
Tripelennamine—Chlorphenamine—CYP2D6—Parkinson's disease	0.000196	0.0146	CrCbGaD
Tripelennamine—Imipramine—SLC6A3—Parkinson's disease	0.000191	0.0142	CrCbGaD
Tripelennamine—Dextropropoxyphene—CYP2D6—Parkinson's disease	0.000189	0.0141	CrCbGaD
Tripelennamine—Doxepin—DRD2—Parkinson's disease	0.000182	0.0136	CrCbGaD
Tripelennamine—Tamoxifen—CYP2E1—Parkinson's disease	0.000176	0.0131	CrCbGaD
Tripelennamine—Orphenadrine—CYP2E1—Parkinson's disease	0.000171	0.0127	CrCbGaD
Tripelennamine—Imipramine—HTR1A—Parkinson's disease	0.000167	0.0124	CrCbGaD
Tripelennamine—Amitriptyline—HTR1A—Parkinson's disease	0.000166	0.0124	CrCbGaD
Tripelennamine—Promazine—DRD2—Parkinson's disease	0.000162	0.0121	CrCbGaD
Tripelennamine—Bepridil—ABCB1—Parkinson's disease	0.000145	0.0108	CrCbGaD
Tripelennamine—Imipramine—DRD2—Parkinson's disease	0.000142	0.0106	CrCbGaD
Tripelennamine—Amitriptyline—DRD2—Parkinson's disease	0.000141	0.0105	CrCbGaD
Tripelennamine—Doxepin—HTR2A—Parkinson's disease	0.000141	0.0105	CrCbGaD
Tripelennamine—Imipramine—CYP2E1—Parkinson's disease	0.000137	0.0102	CrCbGaD
Tripelennamine—Amitriptyline—CYP2E1—Parkinson's disease	0.000136	0.0101	CrCbGaD
Tripelennamine—Diphenhydramine—CYP2D6—Parkinson's disease	0.000133	0.00988	CrCbGaD
Tripelennamine—Tamoxifen—CYP2D6—Parkinson's disease	0.000129	0.00962	CrCbGaD
Tripelennamine—Doxepin—CYP2D6—Parkinson's disease	0.000129	0.00959	CrCbGaD
Tripelennamine—Methadone—CYP2D6—Parkinson's disease	0.000128	0.00954	CrCbGaD
Tripelennamine—Promazine—HTR2A—Parkinson's disease	0.000125	0.00932	CrCbGaD
Tripelennamine—Imipramine—HTR2A—Parkinson's disease	0.00011	0.00816	CrCbGaD
Tripelennamine—Amitriptyline—HTR2A—Parkinson's disease	0.000109	0.00811	CrCbGaD
Tripelennamine—Imipramine—CYP2D6—Parkinson's disease	0.0001	0.00746	CrCbGaD
Tripelennamine—Amitriptyline—CYP2D6—Parkinson's disease	9.97e-05	0.00741	CrCbGaD
Tripelennamine—Tamoxifen—ABCB1—Parkinson's disease	9.23e-05	0.00687	CrCbGaD
Tripelennamine—Doxepin—ABCB1—Parkinson's disease	9.2e-05	0.00685	CrCbGaD
Tripelennamine—Methadone—ABCB1—Parkinson's disease	9.15e-05	0.00681	CrCbGaD
Tripelennamine—CYP2D6—Codeine and Morphine Metabolism—ABCB1—Parkinson's disease	8.62e-05	0.0366	CbGpPWpGaD
Tripelennamine—CYP2D6—CYP2E1 reactions—CYP2E1—Parkinson's disease	8.56e-05	0.0363	CbGpPWpGaD
Tripelennamine—Imipramine—ABCB1—Parkinson's disease	7.16e-05	0.00533	CrCbGaD
Tripelennamine—Amitriptyline—ABCB1—Parkinson's disease	7.12e-05	0.00529	CrCbGaD
Tripelennamine—HRH1—Monoamine GPCRs—HTR1A—Parkinson's disease	6.77e-05	0.0287	CbGpPWpGaD
Tripelennamine—HRH1—Monoamine GPCRs—DRD1—Parkinson's disease	6.54e-05	0.0277	CbGpPWpGaD
Tripelennamine—CYP2D6—Fatty Acid Omega Oxidation—CYP2E1—Parkinson's disease	6.34e-05	0.0269	CbGpPWpGaD
Tripelennamine—HRH1—Monoamine GPCRs—DRD3—Parkinson's disease	6.33e-05	0.0269	CbGpPWpGaD
Tripelennamine—HRH1—Monoamine GPCRs—HTR7—Parkinson's disease	5.73e-05	0.0243	CbGpPWpGaD
Tripelennamine—HRH1—Monoamine GPCRs—DRD2—Parkinson's disease	5.73e-05	0.0243	CbGpPWpGaD
Tripelennamine—HRH1—Amine ligand-binding receptors—HTR1A—Parkinson's disease	5.69e-05	0.0241	CbGpPWpGaD
Tripelennamine—HRH1—Amine ligand-binding receptors—DRD1—Parkinson's disease	5.5e-05	0.0233	CbGpPWpGaD
Tripelennamine—HRH1—Amine ligand-binding receptors—DRD3—Parkinson's disease	5.32e-05	0.0226	CbGpPWpGaD
Tripelennamine—CYP2D6—Xenobiotics—CYP2E1—Parkinson's disease	5.31e-05	0.0225	CbGpPWpGaD
Tripelennamine—CYP2D6—Tamoxifen metabolism—CYP2E1—Parkinson's disease	5.1e-05	0.0216	CbGpPWpGaD
Tripelennamine—HRH1—Amine ligand-binding receptors—DRD2—Parkinson's disease	4.82e-05	0.0204	CbGpPWpGaD
Tripelennamine—HRH1—Amine ligand-binding receptors—HTR7—Parkinson's disease	4.82e-05	0.0204	CbGpPWpGaD
Tripelennamine—HRH1—G alpha (q) signalling events—DGKQ—Parkinson's disease	4.18e-05	0.0177	CbGpPWpGaD
Tripelennamine—HRH1—Monoamine GPCRs—HTR2A—Parkinson's disease	4.01e-05	0.017	CbGpPWpGaD
Tripelennamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—DGKQ—Parkinson's disease	3.74e-05	0.0159	CbGpPWpGaD
Tripelennamine—HRH1—Amine ligand-binding receptors—HTR2A—Parkinson's disease	3.37e-05	0.0143	CbGpPWpGaD
Tripelennamine—CYP2D6—Melatonin metabolism and effects—MAOA—Parkinson's disease	3.24e-05	0.0138	CbGpPWpGaD
Tripelennamine—HRH1—GPCRs, Class A Rhodopsin-like—GPR37—Parkinson's disease	3.23e-05	0.0137	CbGpPWpGaD
Tripelennamine—HRH1—G alpha (q) signalling events—GRK5—Parkinson's disease	3.17e-05	0.0134	CbGpPWpGaD
Tripelennamine—CYP2D6—Melatonin metabolism and effects—EDN1—Parkinson's disease	3.02e-05	0.0128	CbGpPWpGaD
Tripelennamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—GRK5—Parkinson's disease	2.83e-05	0.012	CbGpPWpGaD
Tripelennamine—HRH1—Class A/1 (Rhodopsin-like receptors)—GPR37—Parkinson's disease	2.77e-05	0.0117	CbGpPWpGaD
Tripelennamine—CYP2D6—Phase 1 - Functionalization of compounds—MAOB—Parkinson's disease	2.63e-05	0.0111	CbGpPWpGaD
Tripelennamine—CYP2D6—Melatonin metabolism and effects—APOE—Parkinson's disease	2.46e-05	0.0104	CbGpPWpGaD
Tripelennamine—HRH1—G alpha (q) signalling events—GRM5—Parkinson's disease	2.29e-05	0.00972	CbGpPWpGaD
Tripelennamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2E1—Parkinson's disease	2.2e-05	0.00934	CbGpPWpGaD
Tripelennamine—CYP2D6—Oxidation by Cytochrome P450—CYP2E1—Parkinson's disease	2.17e-05	0.00922	CbGpPWpGaD
Tripelennamine—HRH1—GPCR ligand binding—GPR37—Parkinson's disease	2.11e-05	0.00895	CbGpPWpGaD
Tripelennamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—GRM5—Parkinson's disease	2.05e-05	0.00869	CbGpPWpGaD
Tripelennamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2E1—Parkinson's disease	1.79e-05	0.00758	CbGpPWpGaD
Tripelennamine—HRH1—Class A/1 (Rhodopsin-like receptors)—PENK—Parkinson's disease	1.78e-05	0.00757	CbGpPWpGaD
Tripelennamine—HRH1—G alpha (q) signalling events—TAC1—Parkinson's disease	1.66e-05	0.00706	CbGpPWpGaD
Tripelennamine—HRH1—Class A/1 (Rhodopsin-like receptors)—PDYN—Parkinson's disease	1.63e-05	0.00692	CbGpPWpGaD
Tripelennamine—CYP2D6—Biological oxidations—GSTA4—Parkinson's disease	1.57e-05	0.00664	CbGpPWpGaD
Tripelennamine—CYP2D6—Metapathway biotransformation—GSTA4—Parkinson's disease	1.54e-05	0.00655	CbGpPWpGaD
Tripelennamine—HRH1—GPCRs, Class A Rhodopsin-like—ADORA2A—Parkinson's disease	1.51e-05	0.00639	CbGpPWpGaD
Tripelennamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—TAC1—Parkinson's disease	1.49e-05	0.00632	CbGpPWpGaD
Tripelennamine—HRH1—G alpha (q) signalling events—ADRBK1—Parkinson's disease	1.48e-05	0.00626	CbGpPWpGaD
Tripelennamine—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—Parkinson's disease	1.47e-05	0.00623	CbGpPWpGaD
Tripelennamine—HRH1—GPCR ligand binding—GRM4—Parkinson's disease	1.43e-05	0.00608	CbGpPWpGaD
Tripelennamine—CYP2D6—Biological oxidations—MAOB—Parkinson's disease	1.4e-05	0.00592	CbGpPWpGaD
Tripelennamine—HRH1—GPCR ligand binding—PENK—Parkinson's disease	1.36e-05	0.00577	CbGpPWpGaD
Tripelennamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—ADRBK1—Parkinson's disease	1.32e-05	0.0056	CbGpPWpGaD
Tripelennamine—HRH1—GPCRs, Class A Rhodopsin-like—HTR1A—Parkinson's disease	1.31e-05	0.00554	CbGpPWpGaD
Tripelennamine—HRH1—Class A/1 (Rhodopsin-like receptors)—ADORA2A—Parkinson's disease	1.29e-05	0.00547	CbGpPWpGaD
Tripelennamine—HRH1—GPCRs, Class A Rhodopsin-like—DRD1—Parkinson's disease	1.26e-05	0.00535	CbGpPWpGaD
Tripelennamine—HRH1—GPCR ligand binding—PDYN—Parkinson's disease	1.24e-05	0.00527	CbGpPWpGaD
Tripelennamine—HRH1—GPCRs, Class A Rhodopsin-like—DRD3—Parkinson's disease	1.22e-05	0.00519	CbGpPWpGaD
Tripelennamine—HRH1—GPCR downstream signaling—DGKQ—Parkinson's disease	1.19e-05	0.00506	CbGpPWpGaD
Tripelennamine—HRH1—GPCR ligand binding—GRM5—Parkinson's disease	1.16e-05	0.0049	CbGpPWpGaD
Tripelennamine—HRH1—G alpha (q) signalling events—EDN1—Parkinson's disease	1.14e-05	0.00486	CbGpPWpGaD
Tripelennamine—HRH1—Class A/1 (Rhodopsin-like receptors)—HTR1A—Parkinson's disease	1.12e-05	0.00475	CbGpPWpGaD
Tripelennamine—HRH1—GPCRs, Class A Rhodopsin-like—HTR7—Parkinson's disease	1.11e-05	0.00469	CbGpPWpGaD
Tripelennamine—HRH1—GPCRs, Class A Rhodopsin-like—DRD2—Parkinson's disease	1.11e-05	0.00469	CbGpPWpGaD
Tripelennamine—HRH1—Class A/1 (Rhodopsin-like receptors)—TAC1—Parkinson's disease	1.1e-05	0.00468	CbGpPWpGaD
Tripelennamine—HRH1—Signaling by GPCR—GPR37—Parkinson's disease	1.08e-05	0.00459	CbGpPWpGaD
Tripelennamine—HRH1—Signaling by GPCR—DGKQ—Parkinson's disease	1.08e-05	0.00459	CbGpPWpGaD
Tripelennamine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD1—Parkinson's disease	1.08e-05	0.00459	CbGpPWpGaD
Tripelennamine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD3—Parkinson's disease	1.05e-05	0.00444	CbGpPWpGaD
Tripelennamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—Parkinson's disease	1.02e-05	0.00434	CbGpPWpGaD
Tripelennamine—HRH1—G alpha (q) signalling events—HTR2A—Parkinson's disease	1e-05	0.00425	CbGpPWpGaD
Tripelennamine—HRH1—Signaling by GPCR—PPP1R1B—Parkinson's disease	9.9e-06	0.0042	CbGpPWpGaD
Tripelennamine—HRH1—GPCR ligand binding—ADORA2A—Parkinson's disease	9.83e-06	0.00417	CbGpPWpGaD
Tripelennamine—CYP2D6—Biological oxidations—CYP2E1—Parkinson's disease	9.49e-06	0.00402	CbGpPWpGaD
Tripelennamine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD2—Parkinson's disease	9.47e-06	0.00402	CbGpPWpGaD
Tripelennamine—HRH1—Class A/1 (Rhodopsin-like receptors)—HTR7—Parkinson's disease	9.47e-06	0.00402	CbGpPWpGaD
Tripelennamine—CYP2D6—Metapathway biotransformation—CYP2E1—Parkinson's disease	9.36e-06	0.00397	CbGpPWpGaD
Tripelennamine—HRH1—GPCR downstream signaling—GRK5—Parkinson's disease	9.03e-06	0.00383	CbGpPWpGaD
Tripelennamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Parkinson's disease	8.96e-06	0.0038	CbGpPWpGaD
Tripelennamine—HRH1—GPCR ligand binding—HTR1A—Parkinson's disease	8.53e-06	0.00362	CbGpPWpGaD
Tripelennamine—HRH1—GPCR ligand binding—TAC1—Parkinson's disease	8.4e-06	0.00356	CbGpPWpGaD
Tripelennamine—HRH1—GPCR ligand binding—DRD1—Parkinson's disease	8.23e-06	0.00349	CbGpPWpGaD
Tripelennamine—HRH1—Signaling by GPCR—GRK5—Parkinson's disease	8.2e-06	0.00348	CbGpPWpGaD
Tripelennamine—HRH1—GPCR downstream signaling—GRM4—Parkinson's disease	8.1e-06	0.00344	CbGpPWpGaD
Tripelennamine—HRH1—GPCR ligand binding—DRD3—Parkinson's disease	7.98e-06	0.00338	CbGpPWpGaD
Tripelennamine—CYP2D6—Biological oxidations—COMT—Parkinson's disease	7.86e-06	0.00333	CbGpPWpGaD
Tripelennamine—CYP2D6—Biological oxidations—GSTP1—Parkinson's disease	7.82e-06	0.00332	CbGpPWpGaD
Tripelennamine—CYP2D6—Biological oxidations—MAOA—Parkinson's disease	7.8e-06	0.00331	CbGpPWpGaD
Tripelennamine—CYP2D6—Metapathway biotransformation—COMT—Parkinson's disease	7.75e-06	0.00329	CbGpPWpGaD
Tripelennamine—HRH1—GPCRs, Class A Rhodopsin-like—HTR2A—Parkinson's disease	7.74e-06	0.00328	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—VPS35—Parkinson's disease	7.72e-06	0.00327	CbGpPWpGaD
Tripelennamine—CYP2D6—Metapathway biotransformation—GSTP1—Parkinson's disease	7.72e-06	0.00327	CbGpPWpGaD
Tripelennamine—HRH1—GPCR downstream signaling—PENK—Parkinson's disease	7.68e-06	0.00326	CbGpPWpGaD
Tripelennamine—HRH1—Class A/1 (Rhodopsin-like receptors)—EDN1—Parkinson's disease	7.58e-06	0.00322	CbGpPWpGaD
Tripelennamine—HRH1—Signaling by GPCR—GRM4—Parkinson's disease	7.36e-06	0.00312	CbGpPWpGaD
Tripelennamine—HRH1—GPCR ligand binding—HTR7—Parkinson's disease	7.21e-06	0.00306	CbGpPWpGaD
Tripelennamine—HRH1—GPCR ligand binding—DRD2—Parkinson's disease	7.21e-06	0.00306	CbGpPWpGaD
Tripelennamine—CYP2D6—Biological oxidations—GSTM1—Parkinson's disease	7.19e-06	0.00305	CbGpPWpGaD
Tripelennamine—CYP2D6—Metapathway biotransformation—GSTM1—Parkinson's disease	7.09e-06	0.00301	CbGpPWpGaD
Tripelennamine—HRH1—GPCR downstream signaling—PDYN—Parkinson's disease	7.03e-06	0.00298	CbGpPWpGaD
Tripelennamine—HRH1—Signaling by GPCR—PENK—Parkinson's disease	6.98e-06	0.00296	CbGpPWpGaD
Tripelennamine—HRH1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Parkinson's disease	6.63e-06	0.00281	CbGpPWpGaD
Tripelennamine—HRH1—GPCR downstream signaling—GRM5—Parkinson's disease	6.53e-06	0.00277	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—DGKQ—Parkinson's disease	6.39e-06	0.00271	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—GPR37—Parkinson's disease	6.39e-06	0.00271	CbGpPWpGaD
Tripelennamine—HRH1—Signaling by GPCR—PDYN—Parkinson's disease	6.38e-06	0.00271	CbGpPWpGaD
Tripelennamine—HRH1—Signaling by GPCR—GRM5—Parkinson's disease	5.93e-06	0.00252	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—PPP1R1B—Parkinson's disease	5.85e-06	0.00248	CbGpPWpGaD
Tripelennamine—HRH1—GPCR ligand binding—EDN1—Parkinson's disease	5.77e-06	0.00245	CbGpPWpGaD
Tripelennamine—HRH1—GPCR downstream signaling—ADORA2A—Parkinson's disease	5.55e-06	0.00236	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—RIT2—Parkinson's disease	5.11e-06	0.00217	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—ND3—Parkinson's disease	5.1e-06	0.00216	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—MCCC1—Parkinson's disease	5.1e-06	0.00216	CbGpPWpGaD
Tripelennamine—HRH1—GPCR ligand binding—HTR2A—Parkinson's disease	5.05e-06	0.00214	CbGpPWpGaD
Tripelennamine—HRH1—Signaling by GPCR—ADORA2A—Parkinson's disease	5.04e-06	0.00214	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—GRK5—Parkinson's disease	4.85e-06	0.00206	CbGpPWpGaD
Tripelennamine—HRH1—GPCR downstream signaling—HTR1A—Parkinson's disease	4.82e-06	0.00204	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—OMD—Parkinson's disease	4.79e-06	0.00203	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—TALDO1—Parkinson's disease	4.79e-06	0.00203	CbGpPWpGaD
Tripelennamine—HRH1—GPCR downstream signaling—TAC1—Parkinson's disease	4.75e-06	0.00201	CbGpPWpGaD
Tripelennamine—HRH1—GPCR downstream signaling—DRD1—Parkinson's disease	4.65e-06	0.00197	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—NDUFB11—Parkinson's disease	4.54e-06	0.00193	CbGpPWpGaD
Tripelennamine—HRH1—GPCR downstream signaling—DRD3—Parkinson's disease	4.51e-06	0.00191	CbGpPWpGaD
Tripelennamine—HRH1—Signaling by GPCR—HTR1A—Parkinson's disease	4.38e-06	0.00186	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—GRM4—Parkinson's disease	4.35e-06	0.00184	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—GCH1—Parkinson's disease	4.33e-06	0.00184	CbGpPWpGaD
Tripelennamine—HRH1—Signaling by GPCR—TAC1—Parkinson's disease	4.31e-06	0.00183	CbGpPWpGaD
Tripelennamine—HRH1—Signaling by GPCR—DRD1—Parkinson's disease	4.23e-06	0.00179	CbGpPWpGaD
Tripelennamine—HRH1—GPCR downstream signaling—ADRBK1—Parkinson's disease	4.21e-06	0.00179	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—MAG—Parkinson's disease	4.12e-06	0.00175	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—PENK—Parkinson's disease	4.12e-06	0.00175	CbGpPWpGaD
Tripelennamine—HRH1—Signaling by GPCR—DRD3—Parkinson's disease	4.09e-06	0.00174	CbGpPWpGaD
Tripelennamine—HRH1—GPCR downstream signaling—DRD2—Parkinson's disease	4.08e-06	0.00173	CbGpPWpGaD
Tripelennamine—HRH1—GPCR downstream signaling—HTR7—Parkinson's disease	4.08e-06	0.00173	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—GBA—Parkinson's disease	3.86e-06	0.00164	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—FBP1—Parkinson's disease	3.86e-06	0.00164	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—DBH—Parkinson's disease	3.86e-06	0.00164	CbGpPWpGaD
Tripelennamine—HRH1—Signaling by GPCR—ADRBK1—Parkinson's disease	3.82e-06	0.00162	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—PDYN—Parkinson's disease	3.77e-06	0.0016	CbGpPWpGaD
Tripelennamine—HRH1—Signaling by GPCR—DRD2—Parkinson's disease	3.7e-06	0.00157	CbGpPWpGaD
Tripelennamine—HRH1—Signaling by GPCR—HTR7—Parkinson's disease	3.7e-06	0.00157	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—GFAP—Parkinson's disease	3.54e-06	0.0015	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—GRM5—Parkinson's disease	3.5e-06	0.00149	CbGpPWpGaD
Tripelennamine—HRH1—GPCR downstream signaling—EDN1—Parkinson's disease	3.26e-06	0.00138	CbGpPWpGaD
Tripelennamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Parkinson's disease	3.11e-06	0.00132	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—FGF20—Parkinson's disease	3.07e-06	0.0013	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—ADORA2A—Parkinson's disease	2.98e-06	0.00126	CbGpPWpGaD
Tripelennamine—HRH1—Signaling by GPCR—EDN1—Parkinson's disease	2.96e-06	0.00126	CbGpPWpGaD
Tripelennamine—HRH1—GPCR downstream signaling—HTR2A—Parkinson's disease	2.85e-06	0.00121	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—DDC—Parkinson's disease	2.84e-06	0.0012	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—INSR—Parkinson's disease	2.75e-06	0.00117	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—GSTA4—Parkinson's disease	2.68e-06	0.00114	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—FGB—Parkinson's disease	2.6e-06	0.0011	CbGpPWpGaD
Tripelennamine—HRH1—Signaling by GPCR—HTR2A—Parkinson's disease	2.59e-06	0.0011	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—HTR1A—Parkinson's disease	2.58e-06	0.0011	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—TAC1—Parkinson's disease	2.55e-06	0.00108	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—DRD1—Parkinson's disease	2.5e-06	0.00106	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—DRD3—Parkinson's disease	2.42e-06	0.00103	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—PLA2G6—Parkinson's disease	2.41e-06	0.00102	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—MAOB—Parkinson's disease	2.39e-06	0.00101	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—ADRBK1—Parkinson's disease	2.26e-06	0.000958	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—HTR7—Parkinson's disease	2.19e-06	0.000928	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—DRD2—Parkinson's disease	2.19e-06	0.000928	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—IGF2—Parkinson's disease	1.83e-06	0.000777	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—IGF1R—Parkinson's disease	1.77e-06	0.000751	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—EDN1—Parkinson's disease	1.75e-06	0.000743	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—CTGF—Parkinson's disease	1.74e-06	0.000739	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—CYP2E1—Parkinson's disease	1.62e-06	0.000688	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—NGF—Parkinson's disease	1.61e-06	0.000682	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—NQO1—Parkinson's disease	1.6e-06	0.00068	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—TH—Parkinson's disease	1.58e-06	0.000671	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—HTR2A—Parkinson's disease	1.53e-06	0.00065	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—CYCS—Parkinson's disease	1.52e-06	0.000644	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—APOE—Parkinson's disease	1.42e-06	0.000604	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—COMT—Parkinson's disease	1.34e-06	0.00057	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—GSTP1—Parkinson's disease	1.34e-06	0.000568	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—MAOA—Parkinson's disease	1.33e-06	0.000566	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—HMOX1—Parkinson's disease	1.32e-06	0.00056	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—ABCB1—Parkinson's disease	1.27e-06	0.000537	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—GSTM1—Parkinson's disease	1.23e-06	0.000522	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—INS—Parkinson's disease	1.22e-06	0.000516	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—GPX1—Parkinson's disease	1.18e-06	0.000499	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—MTHFR—Parkinson's disease	1.09e-06	0.000461	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—APOE—Parkinson's disease	1.01e-06	0.000429	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—CASP3—Parkinson's disease	9.06e-07	0.000384	CbGpPWpGaD
Tripelennamine—HRH1—Signaling by GPCR—IL6—Parkinson's disease	9e-07	0.000382	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—INS—Parkinson's disease	8.64e-07	0.000367	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—MAPK8—Parkinson's disease	8.32e-07	0.000353	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—IL6—Parkinson's disease	5.31e-07	0.000225	CbGpPWpGaD
